Northwest Biotherapeutics Acquires Flaskworks

Northwest Biotherapeutics Acquires Advent BioServices Ltd.

October 26, 2025

Biotechnology

Northwest Biotherapeutics (NWBio) has completed the acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. The deal transfers Advent's fixed assets, intellectual property and cryostorage capabilities to NWBio to support scale-up and integration of manufacturing capacity for NWBio's DCVax immunotherapy programs.

Illumina Acquires Fluent BioSciences

July 9, 2024

Biotechnology

Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.

Ajinomoto Co., Inc. Acquires Forge Biologics

November 13, 2023

Biotechnology

Ajinomoto Co., Inc. will acquire Forge Biologics in an all-cash transaction valued at $620 million, expanding Ajinomoto's gene therapy and plasmid/AAV manufacturing capabilities. Forge, a Columbus, Ohio–based viral vector and plasmid CDMO with a 200,000 sq ft cGMP facility and ~300+ employees, will become a consolidated subsidiary to accelerate global gene and cell therapy manufacturing capacity.

ProMach Acquires Pharmaworks

March 9, 2020

Packaging

ProMach has acquired Pharmaworks, a Florida-based provider of blister packaging and thermoforming machinery, expanding ProMach's pharmaceutical packaging capabilities and integrated solutions. Pharmaworks’ team of over 100 employees and its lineup of blister packaging systems, inspection, and aftermarket services will join ProMach’s pharma business line to broaden its product offering and support for pharmaceutical, consumer goods, and contract packaging customers.

New England Biolabs Acquires Fluorogenics Limited

May 10, 2021

Biotechnology

New England Biolabs (NEB) has agreed to acquire Fluorogenics Limited (FGL), a UK-based lyophilization R&D and ISO 13485-certified service provider. FGL will become a wholly owned subsidiary of NEB as NEB integrates lyophilization capabilities into its OEM and Customized Solutions offering to better serve molecular and point-of-care diagnostics customers.

Merck KGaA Acquires SpringWorks Therapeutics for $3.4B

July 1, 2025

Pharmaceuticals

Merck KGaA, Darmstadt, Germany completed the acquisition of SpringWorks Therapeutics, Inc. for an enterprise value of $3.4 billion (US$47 per share in cash), following regulatory clearances and customary closing conditions. The deal adds SpringWorks' rare tumor portfolio — including OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib) — to Merck's Healthcare business and is expected to be accretive to earnings by 2027 while strengthening Merck's rare tumor capabilities.